VCS
GSK icon

Vaughan & Co Securities’s GSK GSK Stock Holding History

Vaughan & Co Securities’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$851K Sell
16,231
-642
-4% -$34K 0.4% 23
2026
Q1 		$931K Sell
16,873
-784
-4% -$42.5K 0.48% 22
2025
Q4 		$866K Sell
17,657
-1,361
-7% -$63.5K 0.45% 22
2025
Q3 		$821K Buy
19,018
+379
+2% +$14.8K 0.44% 22
2025
Q2 		$716K Sell
18,639
-69
-0.4% -$2.64K 0.41% 29
2025
Q1 		$725K Buy
18,708
+4,805
+35% +$176K 0.45% 28
2024
Q4 		$470K Sell
13,903
-59
-0.4% -$2.12K 0.28% 47
2024
Q3 		$571K Sell
13,962
-55
-0.4% -$2.25K 0.34% 43
2024
Q2 		$540K Sell
14,017
-616
-4% -$25.9K 0.34% 44
2024
Q1 		$627K Sell
14,633
-1,827
-11% -$75.3K 0.4% 35
2023
Q4 		$610K Sell
16,460
-529
-3% -$19K 0.41% 40
2023
Q3 		$616K Sell
16,989
-207
-1% -$7.35K 0.46% 28
2023
Q2 		$613K Sell
17,196
-90
-0.5% -$3.23K 0.44% 36
2023
Q1 		$615K Sell
17,286
-6,773
-28% -$237K 0.46% 38
2022
Q4 		$845K Buy
+24,059
New +$801K 0.67% 20
2022
Q3 		– Sell
-13,334
Closed -$726K – 52
2022
Q2 		$726K Sell
13,334
-160
-1% -$8.83K 0.58% 27
2022
Q1 		$735K Sell
13,494
-104
-0.8% -$5.65K 0.51% 30
2021
Q4 		$750K Buy
13,598
+415
+3% +$21.6K 0.51% 25
2021
Q3 		$630K Hold
13,183
– – 0.47% 31
2021
Q2 		$656K Hold
13,183
– – 0.48% 29
2021
Q1 		$588K Buy
13,183
+4,197
+47% +$190K 0.47% 33
2020
Q4 		$414K Sell
8,986
-250
-3% -$11.5K 0.37% 37
2020
Q3 		$435K Hold
9,236
– – 0.45% 29
2020
Q2 		$471K Sell
9,236
-913
-9% -$46.8K 0.52% 27
2020
Q1 		$481K Sell
10,149
-26
-0.3% -$1.39K 0.61% 20
2019
Q4 		$598K Buy
+10,175
New +$566K 0.54% 29

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vaughan & Co Securities's GSK Position: Q2 2026 in Review

Vaughan & Co Securities reduced its GSK (GSK) stake by 3.8% in Q2 2026, selling an estimated $34K and leaving 16,231 shares worth $851K. The position accounts for 0.4% of the portfolio, ranked #23.

Vaughan & Co Securities first reported a position in GSK in Q4 2019 and has held it in 26 quarters since. The position peaked at $931K in Q1 2026. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Vaughan & Co Securities held 16,231 shares of GSK worth $851K as of Q2 2026.
  • Vaughan & Co Securities sold 642 GSK shares in Q2 2026, an estimated $34K.
  • GSK made up 0.4% of Vaughan & Co Securities's portfolio in Q2 2026, its #23 holding.
  • Vaughan & Co Securities first reported a position in GSK in Q4 2019 and has held it in 26 quarters since.
  • Vaughan & Co Securities's GSK position peaked at $931K in Q1 2026.
  • 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Vaughan & Co Securities's 13F filing for Q2 2026, filed 3 Aug 2026.